首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Corrigendum to “Development of an in vivo active,dual EP1 and EP3 selective antagonist based on a novel acyl sulfonamide bioisostere” [Bioorg. Med. Chem. Lett. 23 (2013) 37–41]
Authors:Jason D Downey  Sam A Saleh  Thomas M Bridges  Ryan D Morrison  J Scott Daniels  Craig W Lindsley  Richard M Breyer
Institution:1. Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA;2. Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN 37232, USA;3. Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, TN 37232, USA;4. Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, TN 37232, USA;5. Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA;6. Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA;7. Department of Medicine, Veterans Affairs Hospital, Nashville, TN 37232, USA;1. Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA;2. Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN 37232, USA;3. Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, TN 37232, USA;4. Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, TN 37232, USA;5. Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA;6. Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA;7. Department of Medicine, Veterans Affairs Hospital, Nashville, TN 37232, USA
Abstract:
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号